The boards of directors of Genzyme Corp. The deal calls for GelTex shareholders to receive 0. The transaction will require the approval of GelTex shareholders, and is subject to customary closing conditions. One of the more intriguing aspects of the Collins study was its analysis of patient Medicare payment histories.
Polymer technology has wide ranging applications, and polymer-based products enjoy a relatively quick development pathway and have proven to be very safe. The companies said the drug is the only calcium-free medication of its kind. GelTex makes Renagel, a medication used to treat patients with late-stage renal disease undergoing dialysis.
In a study to be published next month, Allan Collins of the University of Minnesota showed a significant improvement in morbidity and observed improved trends in mortality among Medicare patients treated with Renagel compared with patients treated with calcium binders.
Monday, securing control over a promising new drug to treat dialysis patients. Genzyme expects that this technology will be a consistent and productive source of product candidates to feed its therapeutics pipeline.
The company said it may take a one-time charge in the fourth quarter related to the acquisition and near-term earnings likely will be reduced because of the deal. Genzyme believes that the worldwide market opportunity for Renagel is far greater than originally anticipated.
Worldwide, approximately 1 million people are now on dialysis and the number is expected to reach 1. Finally, an additional and significant attribute of Renagel is that it has been shown in clinical studies to dramatically lower LDL cholesterol while increasing HDL cholesterol.
GelTex also developed the new cholesterol-lowering drug WelChol, which is being launched by Sankyo-Parke Davis this month.
The deal is subject to regulatory review and approval by GelTex shareholders. Since these compounds are high-molecular-weight polymers, they are unlikely to be absorbed into the blood stream. Genzyme will receive royalties from sales of WelChol, which is being launched by Sankyo-Parke Davis this month.
The product is being developed and will be commercialized in Japan and other Pacific Rim countries by Chugai Pharmaceuticals and Kirin Pharmaceuticals under agreements with GelTex. In this analysis, Collins found dramatic annual costs savings for patients treated with Renagel. Genzyme General expects that the acquisition of GelTex may result in a one-time charge in the fourth quarter ofrelated to the write-off of in-process research and development.
A Phase 1 trial of GT in normal volunteers was completed in August, and a Phase 2 clinical trial of the product is expected to begin later this year.
With the acquisition, Genzyme obtains two patent-protected, marketed products: A Phase 2 clinical trial of a second-generation version of WelChol will be completed this quarter, and additional clinical trials are planned.
In pre-clinical studies, these compounds have shown they can inhibit lipase with a potency in the range of that of known inhibitors. According to Termeer, Renagel represents "the most important advance in the treatment of dialysis patients since… Epogen. GelTex employs approximately people.
Recent clinical studies have indicated a connection between calcium-based treatments and cardiovascular disease, the leading cause of death in the dialysis population, Genzyme said.
GelTex has also identified polymers that bind fat and prevent the oily stool associated with lipase inhibition. Renagel is a rapidly growing product used in end-stage renal disease; WelChol is a new cholesterol-lowering agent that will be launched this month by Sankyo-Parke Davis.
Terms of the agreement GelTex shareholders will receive 0. The transaction is expected to close in the fourth quarter, pending approval from regulatory agencies and GelTex shareholders. Genzyme will receive royalties from sales of the drug. Such compounds could potentially inhibit fat absorption without causing oily stool side effects associated with current therapy.
In this retrospective analysis of data from the U. Its leading product in development is a toxin binder known as GT for Clostridium difficile C.GenzymeGeltex Pharmaceuticals Joint Venture Case Solution,GenzymeGeltex Pharmaceuticals Joint Venture Case Analysis, GenzymeGeltex Pharmaceuticals Joint Venture Case Study Solution, Proposed Solutions/Alternatives The evaluation of the attractiveness of proposed project is usually analyzed through discounted cash flow.
Early inGenzyme Corporation began negotiations with Geltex Pharmaceuticals in an attempt to launch a joint venture to market Geltex's first product, RenaGel. Geltex was a young biotech research company with only two products in its pipeline, and they didn't have the resources necessary to.
Early inGenzyme Corporation began negotiations with Geltex Pharmaceuticals in an attempt to launch a joint venture to market Geltex's first product, RenaGel. Geltex was a young biotech research company with only two products in its pipeline, and 4/5(2).
In Marchan executive vice president of Genzyme Corporation must develop the terms by which the $ billion (revenue) firm will form a joint venture with a small biotechnology firm to make and market a new drug.
The tasks for the decision maker are to estimate the enterprise value of the new joint venture, recommend how large an.
Sanofi Genzyme is an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition inGenzyme has been a fully owned subsidiary of Sanofi. InGenzyme was the world’s third-largest biotechnology company, employing more than 11, people around the world.
Genzyme General (Cambridge, MA) and GelTex Pharmaceuticals Inc. (Waltham, MA) announced on September 11 that Genzyme will acquire GelTex.
The transaction is expected to close in the fourth quarter, pending approval from regulatory agencies and GelTex shareholders. With the acquisition, Genzyme.Download